In this article, we will discuss the 7 Most Profitable Value Stocks to Buy Right Now.
On April 2, Kevin Mahn, Hennion & Walsh Asset Management president and chief investment officer, joined ‘Squawk Box’ on CNBC to discuss market reactions to developments in the Iran war. The Dow’s 535-point drop on that day highlighted a persistent market cycle in which equities move in the opposite direction of oil prices. Mahn agreed that this market refrain persisted and noted that while prospects for a resolution in Iran drive oil down and stocks up, any delays or escalations cause oil and yields to shoot back up while stocks fall. He anticipated that these bouts of short-term volatility would continue, though he suggested that if a resolution materializes within 2 to 3 weeks, investors will pivot back to underlying market themes based on where capital is being spent through the end of the decade.
Regarding the AI trade and Wall Street’s growing skepticism over high CapEx, Mahn advised focusing on where the money is being spent rather than who is spending it. He used a baseball analogy to argue that the AI revolution is still in batting practice, which represents the current infrastructure build-out. He acknowledged that while return on investment may not be seen for years, the immediate opportunity lies in AI infrastructure. Despite acknowledging that hyperscalers might scale back if sentiment sours, Mahn maintained that spending plans for 2026 are unlikely to change significantly.
Mahn also discussed the impact of high oil prices on the broader economy and noted that the Q1 GDP forecast was recently lowered to 1.9%. He explained that because consumer spending drives 70% of economic growth, sustained high oil prices will inevitably slow the economy by limiting consumer discretionary funds.
Our Methodology
We used screeners to identify stocks that are trading below a forward P/E of 15, as well as reported high TTM net income (at least $1 billion) and TTM net income margin (at least 15%). We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Note: All data was sourced on April 8.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
7 Most Profitable Value Stocks to Buy Right Now
7. AngloGold Ashanti (NYSE:AU)
AngloGold Ashanti (NYSE:AU) is one of the most profitable value stocks to buy right now. On March 30, AngloGold Ashanti announced cash tender offers to purchase three series of its outstanding notes: 3.375% notes due 2028, 3.750% notes due 2030, and 6.500% notes due 2040. The offer is subject to an aggregate purchase cap of $650 million, with a specific sub-cap of $50 million for the 2040 notes. Purchases will be determined based on assigned acceptance priority levels, with the 2028 notes holding the highest priority.
To receive the total consideration (which includes a $50 early tender payment per $1,000 principal amount), holders must validly tender their notes by the early tender deadline of 5:00 p.m. NYC time on April 13. Those who tender after this time but before the final expiration on April 28 will receive only the late tender consideration. All accepted notes will also receive accrued and unpaid interest up to the settlement date, with early settlement expected on April 16 and final settlement on May 1.
The pricing for the offers will be determined at 10:00 a.m. NYC time on April 14, based on a fixed spread over the yield of specified US Treasury securities. The offeror maintains the right to extend, amend, or terminate the offers if certain conditions are not met. Detailed procedures and terms are available on the dedicated offer website and through Kroll Issuer Services Limited.
AngloGold Ashanti is a gold mining company that also deals in other by-products, such as silver and sulphuric acid. The company’s flagship is the 100% owned Geita mine in northwestern Tanzania’s Lake Victoria goldfields.
6. GSK plc (NYSE:GSK)
GSK plc (NYSE:GSK) is one of the most profitable value stocks to buy right now. On March 13, GSK plc announced that the US FDA expanded the approved age indication for its RSV vaccine, AREXVY. The vaccine is now authorized for adults aged 18 to 49 who are at an increased risk for lower respiratory tract disease/LRTD caused by respiratory syncytial virus. This decision follows previous approvals for adults aged 60 and older, as well as those aged 50 to 59 with specific risk factors, though the vaccine remains restricted from use in pregnant individuals.
The FDA expansion is supported by data from a Phase IIIb trial, which showed a non-inferior immune response in the 18 to 49 age group compared to adults aged 60 and older. The safety profile remained consistent with earlier clinical programs, with common side effects including injection site pain, fatigue, and headache. GSK highlighted that this approval addresses a significant medical need, as ~21 million US adults under 50 have at least one risk factor, such as chronic kidney disease, diabetes, or obesity, that increases the likelihood of severe RSV infection.
The annual burden of RSV in the US for adults under 50 includes ~17,000 hospitalizations and ~2 million outpatient visits. GSK executives stated that broadening access to the vaccine will help mitigate these outcomes and reduce pressure on the healthcare system. While the vaccine is now approved for this younger demographic in the US and the European Economic Area, GSK is continuing to pursue further regulatory submissions globally to support its long-term growth objectives for the product.
GSK plc (NYSE:GSK) is a drug manufacturer that specializes in vaccines, specialty medicines, and general medicines to prevent and treat various diseases through its Commercial Operations and Total R&D segments.
5. National Grid (NYSE:NGG)
National Grid (NYSE:NGG) is one of the most profitable value stocks to buy right now. On March 25, GridCARE and National Grid announced a collaboration to accelerate the connection of large-load customers, such as data centers and manufacturers, to the power grid. By using the AI-driven GridCARE Energize platform, the partnership aims to identify underutilized capacity within existing infrastructure, particularly in New York. This approach targets reducing traditional interconnection delays from several years to as little as 6 to 12 months without compromising grid reliability.
The tech uses GenAI and physics-based simulations to evaluate quadrillions of operating scenarios, identifying specific conditions where the grid is underused. By integrating operational strategies like battery storage and distributed energy assets, the platform unlocks hidden megawatts from assets that currently operate at roughly one-third utilization. This strategy allows utilities to deliver power to high-demand AI and industrial projects using infrastructure that is already built and paid for.
The initiative is designed to support economic growth while protecting customer affordability by spreading fixed network costs across a broader load base. GridCARE, founded at Stanford’s Doerr School, has reportedly unlocked over $10 billion in economic value to date by bringing hundreds of megawatts of power online years ahead of traditional schedules.
National Grid is a utilities company that transmits and distributes electricity and gas. The company has several segments: UK Electricity Transmission, UK Electricity Distribution, New England, New York, National Grid Ventures, and Other.
4. Amgen Inc. (NASDAQ:AMGN)
Amgen Inc. (NASDAQ:AMGN) is one of the most profitable value stocks to buy right now. On April 6, Amgen announced positive topline results from a Phase 3 trial evaluating a subcutaneous formulation of TEPEZZA for patients with moderate-to-severe active Thyroid Eye Disease. The study used an on-body injector to deliver the medicine every two weeks, demonstrating efficacy comparable to the currently approved intravenous/IV version.
The trial successfully met its primary endpoint, with 77% of participants achieving a significant proptosis response (a reduction in eye bulging) compared to ~20% in the placebo group. The secondary endpoints also showed clinically meaningful improvements, including a mean proptosis reduction of 3.17 mm at week 24 and enhanced quality-of-life scores. Other benefits included positive responses in diplopia (double vision) and clinical activity scores.
Amgen Inc. leadership noted that this subcutaneous option could evolve the standard of care by offering a more convenient and accessible delivery method for the 25,000+ patients who have historically relied on IV infusions. The safety profile for the subcutaneous administration was generally consistent with the established IV profile, with the addition of mild-to-moderate injection site reactions.
Amgen Inc. is a drug manufacturer that delivers human therapeutics through pharmaceutical wholesale distributors. The company was founded in 1980 and is headquartered in California.
3. Gilead Sciences Inc. (NASDAQ:GILD)
Gilead Sciences Inc. (NASDAQ:GILD) is one of the most profitable value stocks to buy right now. On April 7, Gilead Sciences announced its agreement to acquire Germany-based Tubulis GmbH for up to $5 billion. This transaction includes an upfront cash payment of $3.15 billion, with an additional $1.85 billion contingent on the achievement of specific milestones. This acquisition is part of a broader effort by Gilead to support its oncology pipeline as it faces declining sales of its COVID-19 treatment, Veklury, and looming patent expiries on other key products.
Through this deal, Gilead gains access to Tubulis’ portfolio of guided missiles, scientifically known as antibody-drug conjugates/ADCs. These experimental cancer treatments are designed to deliver chemotherapy directly to malignant cells, thereby minimizing damage to healthy tissue and reducing side effects. This move follows other recent high-value acquisitions, including the $7.8 billion purchase of Arcellx in February and the $2 billion acquisition of Ouro Medicines in March, as Gilead pivots toward high-growth areas like cancer and immune disorder treatments.
The acquisition reflects a continuing spree of deal-making intended to transform Gilead beyond its traditional dominance in virology. By integrating Tubulis’ ADC platform, Gilead Sciences Inc. aims to strengthen its position in the competitive oncology market. This investment aligns with the company’s recent history of aggressive expansion into cell therapy and precision medicine to secure long-term revenue streams in the face of shifting market dynamics.
Gilead Sciences Inc. is a drug manufacturer that develops medicines for unmet medical needs. The company provides treatments for HIV-1, chronic hepatitis C, primary biliary cholangitis, chronic hepatitis B, and serious invasive fungal infections. It also offers T-cell and CAR T-cell therapies for adult patients, intravenous injections, and treatments for COVID-19.
2. AT&T Inc. (NYSE:T)
AT&T Inc. (NYSE:T) is one of the most profitable value stocks to buy right now. On March 31, AT&T reached a $2 billion agreement to enhance FirstNet, the federal emergency cellular network. Under the terms of the deal, the telecommunications giant will invest ~$1 billion directly into improving the program’s infrastructure. The remaining $1 billion in value will be delivered through significant cost savings for the program via reduced service rates for users.
This strategic update was facilitated by a 2025 executive order from President Donald Trump, which directed federal agencies to review all existing contracts for efficiency. The FirstNet system was originally awarded to AT&T Inc. in 2017 as part of a 25-year contract, following recommendations made after the 9/11 attacks to establish a dedicated communication line for first responders.
Currently, FirstNet is utilized by 31,000 US agencies, providing a unified network for police, firefighters, and medical personnel. AT&T’s President of Public Sector, Wes Anderson, emphasized that the agreement reflects the company’s commitment to the public-private partnership. The investment aims to ensure that the mission-critical network remains technologically advanced while lowering the financial burden on the government.
AT&T Inc. is a telecom and tech services company that operates through the Communications and Latin America segments. The Communications segment offers wireline telecom, wireless, and broadband services in the US and globally, while the Latin America segment manages services in Mexico.
1. HSBC Holdings (NYSE:HSBC)
HSBC Holdings (NYSE:HSBC) is one of the most profitable value stocks to buy right now. On March 23, HSBC appointed David Rice as its first Chief AI Officer, a newly created role aimed at integrating GenAI across the bank’s global operations. Rice previously served as the Chief Operating Officer for HSBC’s Corporate and Institutional Banking division. While many global banks include AI oversight within the broader responsibilities of a Chief Technology Officer, HSBC’s decision to establish a dedicated head for this technology marks a distinct shift in its leadership structure.
CEO Georges Elhedery has identified AI as a primary driver for the bank’s strategic goals, specifically targeting a return on tangible equity of over 17% for the 2026–2028 period. During a February 25 conference call, Elhedery informed investors that GenAI represents the bank’s largest current technology investment. The initiative focuses on automating and streamlining internal processes, mirroring a wider industry trend where financial institutions are utilizing AI to enhance coding, fraud detection, and credit application workflows.
The push for increased automation is closely tied to cost-cutting efforts, though the bank has not yet confirmed specific figures regarding potential workforce reductions. While HSBC Holdings has not officially disclosed job cuts, reports earlier this month suggested that up to 20,000 roles could eventually be affected as AI capabilities expand. The bank maintains that these plans are in the early stages and that no final decisions regarding personnel have been made.
HSBC Holdings is a financial services company that provides banking & financial products and services globally through its Wealth & Personal Banking, Commercial Banking, and Global Banking & Markets segments.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
